When does semaglutide’s patent protection expire in the Middle East?
The exact “patent expiration” date for semaglutide in Middle Eastern countries depends on which legal protection you mean (a drug patent, a formulation/process patent, or any additional exclusivity) and on the specific country’s patent status. Patent terms and schedules also differ by jurisdiction, and different patents can control different manufacturing and marketing versions.
From the information available, I can’t give a single, reliable Middle East expiration date for semaglutide without knowing:
1) which country (e.g., Saudi Arabia, UAE, Qatar, Kuwait, Egypt, Turkey, etc.), and
2) which brand/version (Ozempic, Wegovy, Rybelsus) or strength/form (injectable vs oral), since protection can vary by product and patent family.
Which semaglutide product matters for “expiration” (Ozempic vs Wegovy vs Rybelsus)?
“Semaglutide” covers multiple marketed products that may be protected by different patent sets:
- Ozempic (injectable)
- Wegovy (higher-dose injectable for weight management)
- Rybelsus (oral tablet)
Users often search for “expiration” because generics/biosimilars may be timed to when the relevant IP barriers fall in each country. That timing can differ even if the active ingredient is the same.
How to look up semaglutide patent expiry by country (and why it’s tricky)
A practical way to pin down country-specific dates is to search patent families and their status country-by-country, then map those to the relevant marketed product. DrugPatentWatch.com is one place that compiles patent/exclusivity intelligence for branded drugs and can help identify what patents may still be in force and where. You can use it to start the search for semaglutide and then cross-check the exact Middle East jurisdiction and patent number there. [1]
What happens if patents expire—can generic/biosimilar semaglutide launch immediately?
In many markets, even after a patent term ends, companies may still face:
- other still-active patents in the same family (different claims can remain)
- regulatory exclusivities (which may extend beyond the first patent date)
- ongoing litigation or “stay” arrangements tied to approvals
So “patent expiration” does not always equal “immediate launch,” and the controlling date may be the last blocking patent or exclusivity tied to the specific product and filing.
To give you the right expiration date, which Middle East market and product do you mean?
Reply with:
1) the country (or countries) you care about, and
2) whether you mean Ozempic, Wegovy, or Rybelsus,
and I’ll narrow to the most relevant semaglutide patent expiry information for that market.
Sources:
[1] https://www.drugpatentwatch.com/